Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502358 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01502358 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 40 participants.
The verdict
NCT01502358, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a new investigational dengue vaccine is safe, well-tolerated, and to see if an immune response against dengue disease will be generated.
Interventions
- BIOLOGICAL Tetravalent Dengue Vaccine (TVDV)
- BIOLOGICAL Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)
- BIOLOGICAL Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01502358
The ClinicalTrials.gov registry entry for NCT01502358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tetravalent Dengue Vaccine (TVDV) is the first listed.
NCT01502358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01502358 about?
NCT01502358 is a clinical study titled "Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease". The purpose of this study is to determine whether a new investigational dengue vaccine is safe, well-tolerated, and to see if an immune response against dengue disease will be generated.
What is the current status of trial NCT01502358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2011-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01502358?
The interventions under investigation include: Tetravalent Dengue Vaccine (TVDV) (BIOLOGICAL), Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose) (BIOLOGICAL), Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01502358?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.